Literature DB >> 31582017

Involvement of TLR4/ CXCL9/ PREX-2 pathway in the development of hepatocellular carcinoma (HCC) and the promising role of early administration of lactobacillus plantarum in Wistar rats.

Asmaa M Elshaer1, Omnyah A El-Kharashi2, Ghada Galal Hamam3, Enas S Nabih4, Yosra M Magdy5, Abeer A Abd El Samad6.   

Abstract

BACKGROUND AND AIM: Improvement of gut microbiota may help in preventing the progression of cirrhosis. We supposed that Lactobacillus Plantarum (L. Plantarum) protects the cirrhotic liver through suppression of TLR4/ CXCL9/ PREX-2.
METHODOLOGY: Rats were divided into two groups. Group I, lasts for six weeks and Group II lasts for 12 weeks. Each group was subdivided into: naïve, Lactobacillus Plantarum (L. Plantarum), thioacetamide (TAA) and TAA + L. Plantarum. Liver function tests, α fetoprotein (AFP) levels, CXCL9, PREX-2 and TLR4 expression were assessed. Histological studies were performed.
RESULTS: TAA induced significant deterioration in liver functions and increased AFP. There was periportal cirrhosis, vacuolated hepatocytes, decrease hepatocyte parrafin-1 (hep par-1) expression, increase proliferating cell nuclear antigen (PCNA) positive nuclei and cytokeratin AE1/AE3. The PCR results showed significant increase in TLR4, CXCL9 and PREX-2 expression. Early administration of L. Plantarum significantly decreased the expression of TLR4, CXCL9 and PREX-2 together with improvement in liver function and prevented the pathological changes.
CONCLUSIONS: The cirrhotic complications induced by TAA are through activation of TLR4/ CXCL9/ PREX-2 pathway and could be prevented by the early administration of L. Plantarum.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CXCL9; Lactobacillus Plantarum; TLR4; Thioacetamide

Mesh:

Substances:

Year:  2019        PMID: 31582017     DOI: 10.1016/j.tice.2019.07.010

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  4 in total

Review 1.  Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy.

Authors:  Wenyu Luo; Shiqi Guo; Yang Zhou; Jingwen Zhao; Mengyao Wang; Lixuan Sang; Bing Chang; Bingyuan Wang
Journal:  Front Microbiol       Date:  2022-04-27       Impact factor: 6.064

Review 2.  Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.

Authors:  Edda Russo; Camila Fiorindi; Francesco Giudici; Amedeo Amedei
Journal:  World J Hepatol       Date:  2022-02-27

Review 3.  Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma.

Authors:  Wasitha P D Wass Thilakarathna; H P Vasantha Rupasinghe; Neale D Ridgway
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

Review 4.  Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer.

Authors:  Chenchen Bi; Geqiong Xiao; Chunyan Liu; Junwei Yan; Jiaqi Chen; Wenzhang Si; Jian Zhang; Zheng Liu
Journal:  Front Cell Dev Biol       Date:  2021-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.